Curis vs Ensysce Biosciences
Curis is the larger business, with $9.4m of revenue in fiscal 2025 against $5.1m for Ensysce Biosciences (1.9 times as much). Ensysce Biosciences grew faster (-2.8% against -13.4%). Curis kept more of each dollar of sales as profit: a net margin of -80.3% against -200.8%. Curis carries less debt relative to equity (0.0% against 9.5%).
| Latest fiscal year | CurisCRIS, 2025 | Ensysce BiosciencesENSC, 2025 |
|---|---|---|
| Revenue | $9.4m | $5.1m |
| Revenue growth | -13.4% | -2.8% |
| Net income | −$7.6m | −$10.2m |
| Operating margin | -60.5% | -202.1% |
| Net margin | -80.3% | -200.8% |
| Return on equity | — | — |
| Free cash flow | −$27.2m | −$7.9m |
| Cash | $5.1m | $4.3m |
| Total debt | $0 | $306,708 |
| Debt to equity | 0.0% | 9.5% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 24 | — |
| Market value | $1.4m | $5.9m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 1 buys, 0 sales | 2 buys, 0 sales |